A new trading day began on Monday, with Avalo Therapeutics Inc (NASDAQ: AVTX) stock price up 10.71% from the previous day of trading, before settling in for the closing price of $17.56. AVTX’s price has ranged from $3.39 to $19.41 over the past 52 weeks.
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 56.49%. Meanwhile, its annual earnings per share averaged 67.66%. With a float of $15.44 million, this company’s outstanding shares have now reached $17.83 million.
Avalo Therapeutics Inc (AVTX) Insider Activity
As we move forward, let’s examine how large-scale investors are investing in this stock of the Biotechnology Industry. The insider ownership of Avalo Therapeutics Inc is 14.85%, while institutional ownership is 72.88%. The most recent insider transaction that took place on Nov 14 ’25, was worth 162,937. In this transaction Director of this company sold 11,367 shares at a rate of $14.33, taking the stock ownership to the 0 shares.
Avalo Therapeutics Inc (AVTX) Earnings and Forecasts
In its latest quarterly report, released on 12/31/2024, the company reported earnings of -2.74 per share, which was $0.1 lower than the consensus estimate of $0.26. In terms of return on equity, this company recorded -19.55% in contrast with 50.0% return on Investment (trailing twelve months). Wall Street market experts anticipate that the next fiscal year will bring earnings of -1.81 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 67.66% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 42.97% during the next five years compared to 56.49% growth over the previous five years of trading.
Avalo Therapeutics Inc (NASDAQ: AVTX) Trading Performance Indicators
Here are Avalo Therapeutics Inc’s current performance indicators. According to the last quarter’s results, the stock had a quick ratio of 14.28. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 1855.37.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -8.73, a number that is poised to hit -1.52 in the next quarter and is forecasted to reach -5.81 in one year’s time.
Technical Analysis of Avalo Therapeutics Inc (AVTX)
Compared to the last year’s volume of 0.2 million, its volume of 0.34 million showed improvement in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 65.94%.
During the past 100 days, Avalo Therapeutics Inc’s (AVTX) raw stochastic average was set at 93.24%, which indicates a significant increase from 79.47% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 1.52 in the past 14 days, which was higher than the 1.16 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $16.11, while its 200-day Moving Average is $9.09. Nevertheless, the first resistance level for the watch stands at $20.65 in the near term. At $21.87, the stock is likely to face the second major resistance level. The third major resistance level sits at $23.28. If the price goes on to break the first support level at $18.02, it is likely to go to the next support level at $16.61. Should the price break the second support level, the third support level stands at $15.39.
Avalo Therapeutics Inc (NASDAQ: AVTX) Key Stats
With a market capitalization of 352.52 million, the company has a total of 18,134K Shares Outstanding. Currently, annual sales are 440 K while annual income is -35,130 K. The company’s previous quarter sales were 0 K while its latest quarter income was -30,630 K.
